4/10
08:58 am
mgnx
MacroGenics (MGNX) was upgraded by B. Riley Financial, Inc. from "neutral" to "buy". They now have a $9.00 price target on the stock.
Medium
Report
MacroGenics (MGNX) was upgraded by B. Riley Financial, Inc. from "neutral" to "buy". They now have a $9.00 price target on the stock.
4/8
05:00 pm
mgnx
FDA Removes Partial Clinical Hold on MacroGenics' LINNET Study [Yahoo! Finance]
Low
Report
FDA Removes Partial Clinical Hold on MacroGenics' LINNET Study [Yahoo! Finance]
4/8
04:30 pm
mgnx
FDA Removes Partial Clinical Hold on MacroGenics’ LINNET Study
High
Report
FDA Removes Partial Clinical Hold on MacroGenics’ LINNET Study
3/12
01:21 pm
mgnx
MacroGenics, Inc. (MGNX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
Low
Report
MacroGenics, Inc. (MGNX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]
3/10
04:22 pm
mgnx
MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates [Yahoo! Finance]
Low
Report
MacroGenics (MGNX) Reports Q4 Loss, Tops Revenue Estimates [Yahoo! Finance]
3/10
11:02 am
mgnx
MacroGenics (MGNX) had its price target raised by Barclays PLC from $3.00 to $4.00. They now have an "overweight" rating on the stock.
High
Report
MacroGenics (MGNX) had its price target raised by Barclays PLC from $3.00 to $4.00. They now have an "overweight" rating on the stock.
3/9
04:42 pm
mgnx
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures [Yahoo! Finance]
High
Report
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures [Yahoo! Finance]
3/9
04:01 pm
mgnx
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures
High
Report
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures
2/26
05:30 pm
mgnx
MacroGenics to Participate in Upcoming Investor Conferences
Neutral
Report
MacroGenics to Participate in Upcoming Investor Conferences
2/24
07:01 am
mgnx
MacroGenics (NASDAQ:MGNX) had its "market perform" rating reaffirmed by analysts at Citigroup Inc..
High
Report
MacroGenics (NASDAQ:MGNX) had its "market perform" rating reaffirmed by analysts at Citigroup Inc..
2/23
06:14 pm
mgnx
MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial
Low
Report
MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial